Results 231 to 240 of about 2,708,442 (333)

Alzheimer's Disease: Mechanisms and Therapeutic Advances

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Alzheimer's disease involves Aβ/tau aggregation, neuroinflammation, BBB leakage, gut–brain dysfunction, and mitochondrial damage, causing neuronal loss. Nanodelivery enables combined small‐molecule and targeted therapies. Disease‐modifying biologics/chemicals, including anti‐Aβ antibodies, raise safety and access concerns. Exercise, cognitive training,
Gaoshuang Fu   +4 more
wiley   +1 more source

Utility of Pelvic Floor Therapy and Behavioral Interventions in the Neurogenic Lower Urinary Tract Dysfunction (NLUTD) Population

open access: yesNeurourology and Urodynamics, Volume 45, Issue 8, Page 1493-1499, November 2026.
ABSTRACT Aims Neurogenic lower urinary tract dysfunction (NLUTD) describes a wide range of symptoms depending on neurologic diagnosis and the resulting bladder and sphincter dysfunction. This narrative review is designed to address the question regarding which NLUTD population benefits most from pelvic floor therapy and behavioral interventions, and ...
Sara M. Lenherr
wiley   +1 more source

Fear learning-induced brain dynamics predict individual extinction memory expression following transcranial magnetic stimulation. [PDF]

open access: yesNat Commun
Zhang K   +9 more
europepmc   +1 more source

Real‐Time Neurofeedback Training to Modulate Glutamate‐Glutamine Concentration Using Functional Magnetic Resonance Spectroscopy

open access: yesNMR in Biomedicine, Volume 39, Issue 11, November 2026.
Neurofeedback training with functional magnetic resonance spectroscopy to modulate glutamate‐glutamine (Glx) concentration in the occipital lobes. Participants learned to induce an increase or decrease in Glx concentration with a self‐selected strategy using real‐time feedback about their success or failure.
Zhiyan Wang   +3 more
wiley   +1 more source

Combining Cognitive Training and Brain Stimulation: A Novel Approach to Address Disordered Eating and Antipsychotic‐Induced Weight Gain in People With Severe Mental Illness

open access: yesEarly Intervention in Psychiatry, Volume 20, Issue 11, November 2026.
ABSTRACT Background Antipsychotic‐induced weight gain is a distressing side effect that most often occurs within the first 3–6 months of pharmacological initiation, significantly increasing cardiometabolic risk and mortality in individuals with severe mental illness.
Mariana Lopes   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy